SCHEMBL2792373

SCHEMBL2792373

Cc1ccccc1C(O)(C(=O)O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.55
CYP2D6 P10635 2/20 0.47
HIF1A Q16665 2/20 0.47
CYP1A2 P05177 2/20 0.41
CHRM2 P08172 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
KMT2A Q03164 3/20 0.40
HTT P42858 3/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397521 0.85 MAPT (0.48) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL7066 0.83 CYP2C9 (0.74) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL4823051 0.81 CYP2C9 (0.65) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL1680669 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL9568239 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL1681667 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL5705762 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL11049826 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL20957595 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2
Benzylic Acid SCHEMBL9181980 0.81 CYP2C9 (0.71) CYP2C9CYP2D6HIF1ACYP1A2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114214009-A High-temperature-resistant antistatic pressure-sensitive adhesive and application thereof 襄阳三沃航天薄膜材料有限公司 2022-03-22 CN claimed
CN-117378314-B Ecological restoration method for coal mine area 中国科学院西北高原生物研究所 2025-05-13 CN disclosed
EP-3148518-B1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PRIVATE LTD (IN) 2022-11-30 EP disclosed
CN-115108901-A Synthetic method of alpha-hydroxycarboxylic acid compound 四川大学 2022-09-27 CN disclosed
CN-114214009-A High-temperature-resistant antistatic pressure-sensitive adhesive and application thereof 襄阳三沃航天薄膜材料有限公司 2022-03-22 CN disclosed
CN-114214009-A High-temperature-resistant antistatic pressure-sensitive adhesive and application thereof 襄阳三沃航天薄膜材料有限公司 2022-03-22 CN disclosed
CN-108715729-B Preparation method of flame-retardant antibacterial waterborne polyurethane coating and adhesive 浙江伟涛包装材料有限公司 2021-06-08 CN disclosed
US-10207993-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2019-02-19 US disclosed
US-10100012-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2018-10-16 US disclosed
US-20170334851-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2017-11-23 US disclosed
US-7723356-B2 Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists NOVARTIS AG (CH) 2010-05-25 US disclosed
US-20090155185-A1 MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC MEADE CHRISTOPHER JOHN MONTAGUE 2009-06-18 US disclosed
US-20090048281-A1 (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases NOVARTIS AG (CH) 2009-02-19 US disclosed
CN-101056634-A Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists NOVARTIS AG (CH) 2007-10-17 CN disclosed
EP-1811999-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2007-08-01 EP disclosed
WO-2006048225-A1 QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2006-05-11 WO disclosed
US-20050025718-A1 Medicaments for inhalation comprising an anticholinergic and a betamimetic BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-02-03 US disclosed
US-6696462-B2 CYCLOPROPYLTROPINE CARBOXYLATE DERIVATIVES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-02-24 US disclosed
US-20030207912-A1 Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH. CO. KG (DE) 2003-11-06 US disclosed
EP-0894797-A1 NOVEL AMIDE DERIVATIVES AND INTERMEDIATES FOR THE SYNTHESIS THEREOF TERUMO KABUSHIKI KAISHA (JP) 1999-02-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10100012-B2 Compounds as anti-tubercular agents FNTB, G6PD, PGGT1B CYP2C9 1403/4885CYP2D6 865/4885HIF1A 3155/4885
US-10207993-B2 Compounds as anti-tubercular agents FNTB, G6PD, PGGT1B CYP2C9 1403/4885CYP2D6 865/4885HIF1A 3155/4885
US-20090048281-A1 (R)-3-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-1-(isoxazol-3-ylcarbamoylmethyl)-1-azonia-bicyclo[2.2.2] octane, useful for treating inflammatory or obstructive airways diseases CHRM3, CHRM2, CHRM1 CYP2C9 1533/4885CYP2D6 2336/4885HIF1A 1651/4885
US-20090155185-A1 MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC ADRB2, CHRM3, ADRB1 CYP2C9 1107/4885CYP2D6 280/4885HIF1A 1874/4885
US-20030207912-A1 Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions CHRM1, CHRNA1, CHRNB1 CYP2C9 668/4885CYP2D6 493/4885HIF1A 2301/4885
US-20170334851-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS FNTB, PGGT1B, GGPS1 CYP2C9 2844/4885CYP2D6 1722/4885HIF1A 3358/4885
US-20050025718-A1 Medicaments for inhalation comprising an anticholinergic and a betamimetic ADRB2, CHRM3, ADRB1 CYP2C9 1107/4885CYP2D6 280/4885HIF1A 1874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.